Riferimento farmaci
Mavacamten
Mavacamten is a medicine in the class cardiovascular.
- Classe del farmaco: Cardiovascular
Ultimo aggiornamento Fonti: US FDA label
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Cardiovascular
- Forme farmaceutiche comuni
- capsula
- Interazioni note
- 108 (Controindicata: 20 · Maggiore: 45 · Moderata: 29 · Minore: 14)
- Nomi commerciali
- 2
- Paesi e mercati
- 2
Come agisce
Allosteric, reversible inhibitor selective for cardiac myosin; reduces the number of myosin heads entering power-generating states, lowering systolic and residual diastolic cross-bridge formation, reducing dynamic LVOT obstruction and improving filling pressures.
Dose abituale nell'adulto (sintesi del foglio illustrativo)
Symptomatic NYHA class II-III obstructive HCM: starting dose 5 mg orally once daily without regard to food; titrate among 2.5 mg, 5 mg, 10 mg or 15 mg once daily; maximum 15 mg once daily
Gravidanza e allattamento
- Gravidanza
- Unsafe May cause fetal harm based on animal data; no human data. Effective contraception during treatment and for 4 months after last dose.
- Allattamento
- Unknown Presence in milk, effects on infant and milk production are unknown; weigh benefits of breastfeeding against maternal need.
Effetti indesiderati segnalati
- Dizziness
- Syncope
Avvertenze in evidenza
- Reduces LVEF and can cause heart failure from systolic dysfunction. Echocardiographic LVEF assessment required before and during treatment. Do not initiate if LVEF <55%; interrupt if LVEF <50% or heart failure symptoms or worsening clinical status. Strong CYP2C19 inhibitors and moderate to strong CYP2C19 or CYP3A4 inducers are contraindicated. Available only through the CAMZYOS REMS Program.
Controindicazioni
- Concomitant strong CYP2C19 inhibitors
- Concomitant moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers
Chi deve prestare attenzione
- Heart failure risk higher with serious intercurrent illness or arrhythmia; assess clinical status and LVEF regularly.
- CYP450 interactions may cause heart failure or loss of effectiveness, including with OTC omeprazole, esomeprazole, cimetidine.
- Available only via REMS program; prescribers, patients and pharmacies must be certified/enrolled.
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Interazioni principali (108)
- Apalutamide + Mavacamten Contraindicated
- Carbamazepine + Mavacamten Contraindicated
- Clarithromycin + Mavacamten Contraindicated
- Dexlansoprazole + Mavacamten Contraindicated
- Efavirenz + Mavacamten Contraindicated
- Enzalutamide + Mavacamten Contraindicated
- Eslicarbazepine + Mavacamten Contraindicated
- Esomeprazole + Mavacamten Contraindicated
- Fluconazole + Mavacamten Contraindicated
- Fluoxetine + Mavacamten Contraindicated
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Mavacamten: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Domande frequenti
What is Mavacamten used for?
Mavacamten is a medicine in the class cardiovascular.
What side effects have been reported with Mavacamten?
Dizziness, Syncope. Serious warning: Reduces LVEF and can cause heart failure from systolic dysfunction.
Can Mavacamten be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. May cause fetal harm based on animal data; no human data. Effective contraception during treatment and for 4 months after last dose. Breastfeeding: Unknown. Presence in milk, effects on infant and milk production are unknown; weigh benefits of breastfeeding against maternal need.
What does Mavacamten interact with?
MediHelp lists 108 known interactions for Mavacamten. Contraindicated: 20 · Major: 45 · Moderate: 29 · Minor: 14. The most serious include Apalutamide, Carbamazepine, Clarithromycin.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
